Literature DB >> 3701108

Clindamycin treatment of experimental chronic osteomyelitis due to Staphylococcus aureus.

C W Norden, E Shinners, K Niederriter.   

Abstract

Clindamycin was used alone for treatment of experimental osteomyelitis due to Staphylococcus aureus in rabbits. Treatment with 30 mg/kg of body weight three times a day for 14 days was ineffective in sterilizing infected rabbit bones. In contrast, when given for 28 days, clindamycin sterilized the infected bones of 16 (84%) of 19 rabbits treated. Only one of 14 isolates of S. aureus from rabbits treated for two weeks developed resistance to clindamycin (minimal inhibitory concentration, greater than 100 micrograms/ml); none of three isolates from rabbits in which treatment failed in the four-week treatment group showed resistance to clindamycin. The results of four weeks of treatment with clindamycin for chronic experimental staphylococcal osteomyelitis were significantly better than those obtained with any other single agent used in prior studies and were generally as good as those with combination therapy that included rifampin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3701108     DOI: 10.1093/infdis/153.5.956

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Bone and joint infections.

Authors:  T Louie
Journal:  Can J Infect Dis       Date:  1992-03

2.  Systemic antimicrobial therapy in osteomyelitis.

Authors:  Henry S Fraimow
Journal:  Semin Plast Surg       Date:  2009-05       Impact factor: 2.314

3.  Comparative evaluation of cefazolin and clindamycin in the treatment of experimental Staphylococcus aureus osteomyelitis in rabbits.

Authors:  J T Mader; K Adams; L Morrison
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

4.  Antimicrobial Photodynamic Therapy Involving a Novel Photosensitizer Combined With an Antibiotic in the Treatment of Rabbit Tibial Osteomyelitis Caused by Drug-Resistant Bacteria.

Authors:  Xiujuan Yin; Ziyuan Fang; Yan Fang; Lin Zhu; Jinwen Pang; Tianjun Liu; Zhanjuan Zhao; Jianxi Zhao
Journal:  Front Microbiol       Date:  2022-04-22       Impact factor: 6.064

5.  Antibiotic penetration into rabbit nucleus pulposus with discitis.

Authors:  Liang Zhang; Jing-cheng Wang; Xin-min Feng; Wei-hua Cai; Jian-dong Yang; Ning Zhang
Journal:  Eur J Orthop Surg Traumatol       Date:  2013-09-17

Review 6.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

7.  Comparative evaluation of A-56619, A-56620, and nafcillin in the treatment of experimental Staphylococcus aureus osteomyelitis.

Authors:  J T Mader; L T Morrison; K R Adams
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

Review 8.  Evaluation of quinolones in experimental animal models of infections.

Authors:  W M Scheld
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

9.  Efficacy and safety of clindamycin-based treatment for bone and joint infections: a cohort study.

Authors:  J Courjon; E Demonchy; E Cua; E Bernard; P-M Roger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-09-07       Impact factor: 3.267

10.  An unreported clindamycin adverse reaction: wrist monoarthritis.

Authors:  Ahmad Alikhani; Ebrahim Salehifar
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.